Sherlock Biosciences Leadership

Rahul Dhanda is the CCo-Founder Chief Executive Officer, President & Director of Sherlock Biosciences. Rahul joined T2 Biosystems in January, 2008. He brings over fifteen years of experience in the Life Science industry, both in biotechnology and medical devices. Prior to joining T2 Biosystems, Rahul worked in marketing at Boston Scientific Urology, where he led the team responsible for the Access, Visualization and Laser Lithotripsy franchises, representing roughly $100 million in annual revenue. His responsibilities included upstream and downstream management of mature and breakthrough, platform technologies. Prior to Boston Scientific, Rahul worked in Business Development at Interleukin Genetics, where he held roles of increasing responsibility. While there, he helped negotiate the firm’s acquisition by Alticor, Inc., as well as multiple other deals. Rahul has also worked at Mosaic Technologies, a platform diagnostics company, as well as Harvard Medical School’s Beth Israel Medical Center. Rahul received his MBA from MIT’s Sloan School of Management and his BA from Wesleyan University. He served as a committee member of the AAAS Committee on Scientific Freedom and Responsibility from 2006-2009. Rahul is the author of several publications, and he has authored the first book to address the crossroads between industry and bioethics/public policy, entitled Guiding Icarus: Merging Bioethics with Corporate Interests.

Rahul Dhanda is the CCo-Founder Chief Executive Officer, President & Director of Sherlock Biosciences. Rahul joined T2 Biosystems in January, 2008. He brings over fifteen years of experience in the Life Science industry, both in biotechnology and medical devices. Prior to joining T2 Biosystems, Rahul worked in marketing at Boston Scientific Urology, where he led the team responsible for the Access, Visualization and Laser Lithotripsy franchises, representing roughly $100 million in annual revenue. His responsibilities included upstream and downstream management of mature and breakthrough, platform technologies. Prior to Boston Scientific, Rahul worked in Business Development at Interleukin Genetics, where he held roles of increasing responsibility. While there, he helped negotiate the firm’s acquisition by Alticor, Inc., as well as multiple other deals. Rahul has also worked at Mosaic Technologies, a platform diagnostics company, as well as Harvard Medical School’s Beth Israel Medical Center. Rahul received his MBA from MIT’s Sloan School of Management and his BA from Wesleyan University. He served as a committee member of the AAAS Committee on Scientific Freedom and Responsibility from 2006-2009. Rahul is the author of several publications, and he has authored the first book to address the crossroads between industry and bioethics/public policy, entitled Guiding Icarus: Merging Bioethics with Corporate Interests.